Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.60 |
| ▸ | ITGAV | P06756 | 1/20 | 0.60 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.60 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.60 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.56 |
| ▸ | ELANE | P08246 | 4/20 | 0.53 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | TCF4 | P15884 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26935034 | 0.90 | ITGB3 (0.63) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL29666765 | 0.89 | HDAC4 (0.58) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL29666536 | 0.87 | HDAC4 (0.54) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL29666853 | 0.85 | KLKB1 (0.57) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL29666547 | 0.85 | ERBB2 (0.52) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL29666546 | 0.84 | KRAS (0.56) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL26935056 | 0.84 | ITGB3 (0.61) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL29666836 | 0.84 | HDAC4 (0.57) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL29666725 | 0.84 | HDAC4 (0.56) | KLKB1ELANEPIN1PLAU | |
| SCHEMBL29666543 | 0.84 | PIN1 (0.58) | ITGB3ITGB1ITGAVITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | ITGB3 1422/4885ITGB1 1222/4885ITGAV 910/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | ITGB3 1422/4885ITGB1 1222/4885ITGAV 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.